会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明公开
    • 포스포리파제 C감마 또는 표피성장인자 수용체 저해제를 유효성분으로 포함하는 고혈압 치료 또는 예방용 조성물
    • 用于预防或治疗包含PLCGAMMA或EGFR抑制剂的高血压组合物
    • KR1020130118840A
    • 2013-10-30
    • KR1020130111350
    • 2013-09-16
    • 건국대학교 산학협력단
    • 배영민박상웅
    • A61K31/352A61P9/12
    • A61K31/416A61K31/122Y10S514/929
    • PURPOSE: A composition for preventing or treating hypertension is provided to have the potential to inhibit excessive vasoconstriction by inhibition of EGFR tyrosine kinase and PLC gamma and to be a medicine for hypertension better than the current calcium channel blocker on the market. CONSTITUTION: A composition for preventing or treating hypertension contains epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG 1478, SP600125, or genistein as an active ingredient. An identification method of medicine for preventing or treating hypertension, or a vasodilator compound comprises: a step of reacting the EGFR tyrosine kinase with at least one test compound; and a step of measuring the activity reduction of the EGFR tyrosine kinase and identifying the test compound as the medicine for preventing or treating hypertension, or a vasodilator compound comprises if the activity is decreased.
    • 目的:提供用于预防或治疗高血压的组合物,以具有通过抑制EGFR酪氨酸激酶和PLCγ而抑制过度血管收缩的潜力,并且与目前市场上的钙通道阻滞剂相比,是高血压药物的优势。 构成:用于预防或治疗高血压的组合物含有表皮生长因子受体(EGFR)酪氨酸激酶抑制剂AG1478,SP600125或染料木素作为活性成分。 用于预防或治疗高血压的药物的鉴定方法或血管扩张剂化合物包括:使EGFR酪氨酸激酶与至少一种测试化合物反应的步骤; 以及测定EGFR酪氨酸激酶的活性降低的步骤,鉴定作为预防或治疗高血压的药物的测试化合物,或者血管舒张剂化合物包含活性降低的步骤。